TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Compassion Focused Therapy (CFT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Struggles with issues of shame or self-criticism~* Have an Outcome Questionnaire (OQ-45) total score at or above 64 (i.e., denoting psychiatric distress in the clinical range)~* Are willing to commit to at least 4 sessions of group treatment~* Are willing to complete the OQ-45 and GQ (standardized CAPS measures) on a weekly basis~* Are willing to have group be their primary mode of treatment to ensure group will be the primary vehicle for change~* Are willing to complete the study measures~Exclusion Criteria~* Clients who do not meet criteria or decline to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment as Usual (Type: EXPERIMENTAL): Participants in this arm will receive treatment as usual (TAU) as an intervention.
- Compassion-Focused Therapy (Type: EXPERIMENTAL): Participants in this arm will be enrolled in a CFT group intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have osteoarthritis (OA) of the knee joint based on American College of Rheumatology (ACR) criteria and confirmed with X-rays and ACR functional class of I to III~* Have been on stable dose of prescription Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), celecoxib, tramadol, or acetaminophen of at least 2000 mg per day for at least 20 days in the past month~* Willing to stop all analgesics for OA pain during the study~* Experienced pain while walking in the target knee of 50-90 mm inclusive on 0-100 Visual Analog Scale (VAS) with an increase in pain while walking of at least 10 mm following washout of current Osteoarthritis pain medications at screening~Exclusion Criteria:~* Allergic to LY2951742, celecoxib, other NSAIDS, including aspirin, and similar drugs~* Arthritis of the knee from other causes~* Uncontrolled hypertension~* Have OA pain that requires treatment with potent opioids, systemic corticosteroids, intra-articular injections, duloxetine, or venlafaxine~* Moderate to severe renal impairment~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
- Celecoxib + Placebo (Type: ACTIVE_COMPARATOR): Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
- LY2951742 5 mg + Placebo (Type: EXPERIMENTAL): Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
- LY2951742 50 mg + Placebo (Type: EXPERIMENTAL): Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
- LY2951742 120 mg + Placebo (Type: EXPERIMENTAL): Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
- LY2951742 300 mg + Placebo (Type: EXPERIMENTAL): Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-25 inclusive;~* Self report of daily or near daily nicotine vaping for the prior ≥ 3 months, screening semi-quantitative urine cotinine positive for recent nicotine use, exhaled CO \<10 ppm and score ≥4 on the 10-item E-cigarette Dependence Inventory (ECDI);~* Self-report of no combusted tobacco use in the past 2 months at enrollment;~* Total body weight at screening ≥35 kg (77 lbs) and Body Mass Index (BMI) ≤35 kg/m2;~* Report motivation to quit vaping in the next 30 days;~* Able to understand study procedures and read and write in English;~* Competent and willing to consent to participate in study procedures.~Exclusion Criteria:~* Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion);~* Unwillingness to abstain during the study from using smoking cessation aids other than those provided by the study;~* Unstable medical condition, epilepsy, severe renal impairment;~* Evidence of active problem substance use severe enough in the investigator's opinion to compromise ability to safely participate;~* Prior adverse drug reaction to varenicline;~* Unwilling to provide urine samples;~* Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
- Monitoring only (Type: NO_INTERVENTION): Participants will attend weekly and monthly sessions that will only consist of assessments. No study medication, no behavioral or texting support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Late-initiated Blood Flow Restricted Rehabilitation Exercises After Total Knee Replacement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients included in the EXknee project (Efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee) Jorgensen et al. 2020)~Exclusion Criteria:~* Severe cardiovascular diseases (New York Heart Association class III and IIII), -~* previous stroke incident, thrombosis incident~* Traumatic nerve injury in affected limb~* Unregulated hypertension (Systolic ≥180 or diastolic ≥110 mmHg)~* Spinal cord injury~* Cancer diagnosis and currently undergoing chemo-, immuno-, or radiotherapy~* Inadequacy in written and spoken Danish~* living more than 45 minutes from either Horsens Regional Hospital or Silkeborg Regional Hospital.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- home-based BFRE (Type: EXPERIMENTAL): Patients in the home-based BFRE group will be carefully instructed in how to perform the exercise program with four weekly sessions for 12 weeks (48 training sessions within an 84-day period). Each session will consist of one lower-limb resistance training exercise: sit-to-stand from a \~43 cm high chair. The exercise will consist of four rounds interspaced by a 30-seconds rest pause. The first, second, and third round will consist of 30, 15, 15 repetitions, while the fourth round will be performed until volitional fatigue. The patients will be instructed to perform both the eccentric and concentric contractions at a steady 2-sec pace with, preferably, no time for relaxation in the transition from eccentric to concentric phase (i.e. the bottom is only kissing the chair before reversing the movement upwards). When a patient can perform more than 25 repetitions in the last round, they are encouraged to add external resistance corresponding to around 5 kg.
- Control Group (Type: NO_INTERVENTION): Patients in the control group will performed the same tests 12 months after surgery and 15 months after surgery as the intervention home-based BFRE group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient must give written (personally signed and dated) informed consent before completing any study-related procedure, which means any assessment or evaluation that would not have formed part of the normal medical care of the patient~* Patient must be 18 years old or over~* Patient must have a histologically-confirmed diagnosis of locally advanced or metastatic prostate cancer or presenting a relapse after curative treatment which is amenable to androgen deprivation therapy~* Patient must have an estimated survival time of greater than 8 months according to the investigator's assessment~Exclusion Criteria:~* Patient at risk of a serious complication in the case of tumour flare (vertebral metastases threatening spinal cord compression or with significant obstructive uropathy)~* Patient who underwent a previous surgical castration~* Prostate cancer therapy within 2 months of baseline visit~* Patient with testosterone level below 150 ng/dL at screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1) 1.- Patients in remission with ALL, CLL, AML, CML, MDS will be allowed to participate in this program if their platelet count is \>150K, and the hemoglobin level is at least 8.0g/dl. The patient will receive their autologous platelets cryopreserved in ThromboSol or the fresh random platelets (FRP) whenever the need for such transfusions is determined to be clinically indicated by their physician(s).~Exclusion Criteria:~1) Patients with detectable circulating malignant cells or ongoing marrow involvement by the tumor will not be eligible.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Platelet Transfusion (Type: EXPERIMENTAL): ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years~* Able to comply with study requirement and to provide informed consent~* Outside the context of tutorship and / or guardianship, affiliated to the Social Security Regime and having consented to participate in the ARCMI study.~* Patient receiving ceftriaxone (1 gram or 2 grams per day) in the emergency department~Exclusion Criteria:~* Patients with acute anorectal pathology incompatible with the swabbing strategy or digital rectal examination.~* Prescription of another dosage of ceftriaxone (more than 2 grams per day)~* Patient with inflammatory bowel disease~* Allergy or contraindication to betalactamines and cephalosporins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient under Ceftriaxone treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, adult, out-patients aged between 18 and 85 years~* Patients with documented hospital admission within the previous 3 months before randomization with discharge diagnosis of CHF~* Patients with functional NYHA class II-IV with LVEF \< 40% assessed within the last 3 months~* Patients with blood BNP levels \> 400 pg/ml or NT-ProBNP levels \> 1500 pg/ml~* Patients with CHF due to ischemic heart disease, idiopathic dilated cardiomyopathy (IDC), mitral or aortic insufficiency or hypertension~* Patients with stable conventional treatment with diuretics, ACEI and/or beta-blockers and/or aldosterone antagonists for at least 2 months prior to randomisation, unless documented contraindication or intolerance~Exclusion Criteria:~* Females who are pregnant or plan a pregnancy during the time of the trial, are nursing or are of childbearing potential and not using acceptable methods of contraception. If a female becomes pregnant during the study, she has to be withdrawn immediately~* Patients with current hospitalisation due to heart failure~* Patients with stroke or transient ischemic attack (TIA) within the last 3 months~* Patients with acute coronary syndrome, myocardial infarction, coronary artery bypass or angioplasty within 3 months~* Planned cardiac surgery, revascularization or resynchronization within the study period~* Patients with operable valvular disease or significant obstructive cardiomyopathy~* Patients with bradycardia \[heart rate (HR) \< 50 bpm\]~* Patients with hypotension \[systolic blood pressure (SBP) \< 90 mmHg\]~* Patients with obstructive pneumopathy~* Patients with clinical significant renal failure (creatininemia \> 200 micromol/l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients 18 years of age and older~* admitted to surgical ICU~* diagnosed with hyperactive or mixed delirium~Exclusion Criteria:~* hypoactive delirium~* primary team does not think patient is appropriate to participate~* no oral access (PO or NGT)~* non-English speaking~* contraindication to study medications~* pregnant women or woman of child-bearing age not on documented contraception~* QTc = or greater than 480~* hepatic dysfunction~* decreased platelets or platelet dysfunction~* bleeding disorder, current major bleeding~* history of NMS, epilepsy, or PD~* diagnosis of schizophrenia, bipolar disorder or schizoaffective disorder~* on warfarin or carbapenems~* delirium due to alcohol withdrawal~* treated with antipsychotics for more than 48 hours prior to study enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valproic Acid (Type: EXPERIMENTAL): 1. Start:~   VPA PO/NGT 500 mg BID~2. If need to increase in 24 or more hours:~   VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3. If need to increase in 24 or more hours:~   VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4. If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* T1 or T2 invasive carcinoma of the breast undergoing breast conserving surgery~* Clinically lymph node negative and Memorial Sloan Kettering nomogram estimates 20% or less risk of positive sentinel node~* Tumors 2.5 cm or less in size (clinical preoperative staging)~* Estrogen receptor positive tumors (≥10%)~* Her2 negative/not over-expressed~* Patients 50 years of age or greater~Exclusion Criteria:~* Prior malignancy not in remission~* Active collagen vascular disease requiring active cytotoxic or immunotherapy~* Psychiatric or mental condition which would preclude informed consent~* Prior thoracic radiation which overlaps with IORT field~* Pregnant patients~* Patients \<50 years~* Risk of positive sentinel lymph node \>20% based on nomogram estimates~* Known lymph node metastases (i.e. clinically node positive)~* Patients with invasive lobular carcinoma~* Patients with pure DCIS~* Known multifocal or multicentric tumor~* Patients requiring neoadjuvant chemotherapy~* Patients requiring or choosing mastectomy with or without reconstruction~* Technical contraindications to IORT dose delivery including skin to balloon distance \<7 mm~* Medical contraindication to IORT, radiation or breast conservation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men with obstructive symptoms due to benign prostatic hyperplasia who are also on anticoagulant regimen.~* Anticoagulant regiments include: Aspirin 81mg, Aspirin 325mg, Adenosine diphosphate (ADP) receptor inhibitors, Cilostazol, Dabigatran, Dipyridamole, or Warfarin. The patient will be stable on their dosage regimen for at least 3 months.~* Maximum flow rate \<15ml/s by uroflowmetry.~* International Prostate Symptom Score (IPSS)≥10.~Exclusion Criteria:~* Patients with coagulopathy, INR exceeding 3.~* Anti-coagulation dose changes within 3 months of surgery.~* Patients not medically cleared to undergo surgery for medical reasons.~* Patients with neurogenic bladder (bladder affected due to a neurologic cause).~* Urethral stricture, obstruction due to stricture.~* Suspected bladder or prostate cancer.~* Prostate size greater than 80 cc.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BPH on anticoagulation (Type: None): Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues